While allogeneic CAR-T therapy holds potential to address these challenges, it introduces other complexities, such as labor-intensive genetic engineering strategies involving TCR ablation to prevent GvHD, HLA-I/II ablation to mitigate host cell-mediated allorejection, and CD52 ablation to avoid lymphoid depletion using anti-CD52 antibodies38,43,108,109. The gene discussed is CD52; the disease is graft versus host disease.